Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer

Cell Reports

Volumn 4, Issue 3, 2013, Pages 542-553

  Zhang, Wei ^a   Liu, Yi ^a,c   Sun, Na ^a   Wang, Dan ^a,b   Boyd Kirkup, Jerome ^a   Dou, Xiaoyang ^a   Han, Jing DongJackie ^a  

^a MAX PLANCK INSTITUTE   (Germany)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BEIJING JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; HERMES ANTIGEN; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; RETINOBLASTOMA BINDING PROTEIN 2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR TWIST;

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME DELETION; CLASSIFICATION ALGORITHM; CONTROLLED STUDY; COPY NUMBER VARIATION; DISTANT METASTASIS; DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOMICS; HIGH RISK POPULATION; HUMAN; INTRACELLULAR SIGNALING; LOW RISK POPULATION; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; ONCOGENE K RAS; ONCOGENE SRC; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION;

CLUSTER ANALYSIS; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 84881613268     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.07.010     Document Type: Article

References (37)

1. Andersen P., Gill R. Cox's regression model for counting processes, a large sample study. Ann. Stat. 1982, 10:1100-1120.
2. Arthur, D., and Vassilvitskii, S. (2007). k-means++: the advantages of careful seeding. Proceedings of the Eighteenth Annual ACM-SIAM Symposium on Discrete Algorithms, 1027-1035.
3. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., et al. Gene ontology: tool for the unification of biology. Nat. Genet. 2000, 25:25-29. The Gene Ontology Consortium.
4. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 2008, 40:499-507.
5. Bolton K.L., Tyrer J., Song H., Ramus S.J., Notaridou M., Jones C., Sher T., Gentry-Maharaj A., Wozniak E., Tsai Y.Y., et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat. Genet. 2010, 42:880-884. Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer)Australian Cancer Study (Ovarian Cancer), Ovarian Cancer Association ConsortiumOvarian Cancer Association Consortium.
6. Bonome T., Levine D.A., Shih J., Randonovich M., Pise-Masison C.A., Bogomolniy F., Ozbun L., Brady J., Barrett J.C., Boyd J., Birrer M.J. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008, 68:5478-5486.
7. Boyer L.A., Lee T.I., Cole M.F., Johnstone S.E., Levine S.S., Zucker J.P., Guenther M.G., Kumar R.M., Murray H.L., Jenner R.G., et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122:947-956.
8. Ciriello G., Cerami E., Sander C., Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 2012, 22:398-406.
9. Crijns A.P., Fehrmann R.S., de Jong S., Gerbens F., Meersma G.J., Klip H.G., Hollema H., Hofstra R.M., te Meerman G.J., de Vries E.G., van der Zee A.G. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009, 6:e24.
10. Denkert C., Budczies J., Darb-Esfahani S., Györffy B., Sehouli J., Könsgen D., Zeillinger R., Weichert W., Noske A., Buckendahl A.C., et al. A prognostic gene expression index in ovarian cancer-validation across different independent data sets. J.Pathol. 2009, 218:273-280.
11. Gurney A., Axelrod F., Bond C.J., Cain J., Chartier C., Donigan L., Fischer M., Chaudhari A., Ji M., Kapoun A.M., et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl. Acad. Sci. USA 2012, 109:11717-11722.
12. Halder S.K., Beauchamp R.D., Datta P.K. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 2005, 7:509-521.
13. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
14. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
15. Hartigan J.A., Wong M.A. Algorithm AS 136: a k-means clustering algorithm. Appl. Stat. 1979, 28:100-108.
16. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
17. Jiang C., Xuan Z., Zhao F., Zhang M.Q. TRED: a transcriptional regulatory element database, new entries and other development. Nucleic Acids Res. 2007, 35(Database issue):D137-D140.
18. Johannes L. Test to help determine if ovarian masses are cancer. The Wall Street Journal 2010, March 9, 2010.
19. Kanehisa M., Goto S., Kawashima S., Okuno Y., Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res. 2004, 32(Database issue):D277-D280.
20. Kanehisa M., Goto S., Furumichi M., Tanabe M., Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010, 38(Database issue):D355-D360.
21. Kosary C.L. Chapter 16: Cancer of the Ovary. NIH Pub. No. 07-6215 2007, NIH, Bethesda, MD.
22. Liu Y., Qiao N., Zhu S., Su M., Sun N., Boyd-Kirkup J., Han J.D. A novel Bayesian network inference algorithm for integrative analysis of heterogeneous deep sequencing data. Cell Res. 2013, 23:440-443.
23. Mi H., Guo N., Kejariwal A., Thomas P.D. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res. 2007, 35(Database issue):D247-D252.
24. Monti S., Savage K.J., Kutok J.L., Feuerhake F., Kurtin P., Mihm M., Wu B., Pasqualucci L., Neuberg D., Aguiar R.C., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005, 105:1851-1861.
25. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
26. Schwarz G.E. Estimating the dimension of a model. Ann. Stat. 1978, 6:461-464.
27. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
28. Steffensen K.D., Waldstrøm M., Jeppesen U., Brandslund I., Jakobsen A. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int. J. Gynecol. Cancer 2008, 18:702-710.
29. Tan T.Z., Miow Q.H., Huang R.Y., Wong M.K., Ye J., Lau J.A., Wu M.C., Bin Abdul Hadi L.H., Soong R., Choolani M., et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol. Med. 2013, 5:1051-1066.
30. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
31. Tothill R.W., Tinker A.V., George J., Brown R., Fox S.B., Lade S., Johnson D.S., Trivett M.K., Etemadmoghadam D., Locandro B., et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 2008, 14:5198-5208. Australian Ovarian Cancer Study Group.
32. Vastrik I., D'Eustachio P., Schmidt E., Gopinath G., Croft D., de Bono B., Gillespie M., Jassal B., Lewis S., Matthews L., et al. Reactome: a knowledge base of biologic pathways and processes. Genome Biol. 2007, 8:R39.
33. Vella N., Aiello M., Russo A.E., Scalisi A., Spandidos D.A., Toffoli G., Sorio R., Libra M., Stivala F. 'Genetic profiling' and ovarian cancer therapy. Mol. Med. Rep. 2011, 4:771-777.
34. Verhaak R.G., Tamayo P., Yang J.Y., Hubbard D., Zhang H., Creighton C.J., Fereday S., Lawrence M., Carter S.L., Mermel C.H., et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J.Clin. Invest. 2013, 123:517-525. Cancer Genome Atlas Research Network.
35. Wu G., Feng X., Stein L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 2010, 11:R53.
36. Xia K., Xue H., Dong D., Zhu S., Wang J., Zhang Q., Hou L., Chen H., Tao R., Huang Z., et al. Identification of the proliferation/differentiation switch in the cellular network of multicellular organisms. PLoS Comput. Biol. 2006, 2:e145.
37. Yoshihara K., Tajima A., Yahata T., Kodama S., Fujiwara H., Suzuki M., Onishi Y., Hatae M., Sueyoshi K., Fujiwara H., et al. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS ONE 2010, 5:e9615.